Selective intracoronary administration of glycoprotein IIb/IIIa inhibitors for acute myocardial infarction in a patient with COVID-19 during percutaneous coronary intervention

Q4 Medicine

Kardiologiya i serdechno-sosudistaya khirurgiya Pub Date : 2022-01-01 DOI:10.17116/kardio202215021177

S. A. Korotkikh, O. Shcherbakova, O. Derbenev

引用次数: 0

Abstract

To date, there are still no the targeted studies devoted to acute coronary syndrome or myocardial infarction in patients with COVID-19. The authors report selective intracoronary administration of glycoprotein IIb/IIIa inhibitor for acute myocardial infarction in a patient with COVID-19 during percutaneous coronary intervention. © 2022, Media Sphera Publishing Group. All rights reserved.

查看原文本刊更多论文

冠状动脉介入治疗期间冠状动脉内选择性给药糖蛋白IIb/IIIa抑制剂治疗COVID-19患者急性心肌梗死

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Kardiologiya i serdechno-sosudistaya khirurgiya Medicine-Surgery

CiteScore

0.80

自引率

0.00%

发文量